C07K 16/2845
Against integrin beta2-subunit-containing molecules
Official title: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
C07K16/2845 (Against integrin beta2-subunit-containing molecules) appears on 181 US grants and 253 published applications in this corpus.
Search patents in C07K- Granted patents
- 181
- Published applications
- 253
- Assignees
- 137
- Inventors
- 445
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 13 | 0 |
| 1999 | 9 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 3 |
| 2002 | 3 | 14 |
| 2003 | 11 | 20 |
| 2004 | 7 | 19 |
| 2005 | 6 | 18 |
| 2006 | 6 | 8 |
| 2007 | 5 | 9 |
| 2008 | 8 | 13 |
| 2009 | 3 | 10 |
| 2010 | 3 | 10 |
| 2011 | 7 | 7 |
| 2012 | 3 | 6 |
| 2013 | 7 | 6 |
| 2014 | 2 | 8 |
| 2015 | 2 | 7 |
| 2016 | 6 | 8 |
| 2017 | 3 | 7 |
| 2018 | 3 | 8 |
| 2019 | 5 | 9 |
| 2020 | 4 | 8 |
| 2021 | 7 | 11 |
| 2022 | 3 | 8 |
| 2023 | 5 | 6 |
| 2024 | 4 | 14 |
| 2025 | 1 | 9 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modular platform for targeted therapeutics30 Jun 2026US 12,668,643 B2Ramot at Tel-Aviv University Ltd.
- Antibodies targeting integrin beta-221 Apr 2026US 12,606,628 B2
- Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments31 Mar 2026US 12,590,157 B2Takeda Pharmaceutical Company Limited
- Mutated e. coli enterotoxins as anti-inflammatory agents24 Jun 2025US 12,337,025 B2The Administrators of the Tulane Educational Fund
- Labeling of antibodies30 Jul 2024US 12,048,753 B2Whitehead Institute for Biomedical Research
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Antibodies targeting integrin beta-21 Oct 2026US 2026/0297199 A1
- Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer17 Sep 2026US 2026/0273055 A1Cornell University
- Humanized anti-cd11b antibodies and methods of use thereof13 Aug 2026US 2026/0234267 A1Kaigene, Inc.
- Interleukin-6 (il-6)/signal transducer and activator of transcription 3 (stat3) pathway inhibitors for use in the treatment of granulomatous diseases30 Jul 2026US 2026/0216107 A1UCL Business PLC
Most cited
By later US patents
- Altered polypeptides with increased half-life795US 5,869,046 AGenentech, Inc. · 1999
- Antibody formulation655US 6,171,586 B2Genentech, Inc. · 2001
- Low pH hydrophobic interaction chromatography for antibody purification599US 5,641,870 AGenentech, Inc. · 1997
- Altered polypeptides with increased half-life489US 6,121,022 AGenentech, Inc. · 2000
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004